Compare · CI vs LH
CI vs LH
Side-by-side comparison of The Cigna Group (CI) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $78.96B, about 3.0x LH ($26.36B).
- Over the past year, CI is up 1.0% and LH is up 11.4% - LH leads by 10.4 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- The Cigna Group
- Labcorp Holdings Inc.
- Price
- -
- -
- Market cap
- $78.96B
- $26.36B
- 1M return
- +9.55%
- -1.47%
- 1Y return
- +0.96%
- +11.38%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest CI
- SEC Form 8-K filed by The Cigna Group
- The Cigna Group's Third Quarter 2026 Earnings Release Details
- Cigna Healthcare Introduces Health Sense To Connect Guidance, Benefits and Clinical Support Around Each Person, Improving Affordability and Outcomes
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- The Cigna Group Hosts 2026 Investor Day; Introduces "Lead to One" to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities
- Is Volunteering Good for Your Health? New Research From The Cigna Group Finds a Strong Connection
- Evercore ISI initiated coverage on The Cigna Group with a new price target
- The Cigna Group to Host Investor Day on September 30
- Officer Neville Everett sold $175,259 worth of shares (617 units at $284.05) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 5,053 units (SEC Form 4)
- Officer Evanko Brian C was granted 3,113 shares, increasing direct ownership by 8% to 41,030 units (SEC Form 4)
Latest LH
- Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
- Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
- Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update
- Labcorp Acquires MLM Medical Labs, Expanding Global Central Laboratory and Biomarker Capabilities for Clinical Trials
- SEC Form 4 filed by EVP, CIO & CTO Oyegunwa Akinbolade